A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Inclusion Criteria: - Male or female ≥18 years of age - Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy - Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2 - Adequate hematological, renal and hepatic function - Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners Exclusion Criteria: - Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days - Prior treatment with p300/CBP bromodomain inhibitors - Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide) - Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment - Major surgery within 4 weeks of the first dose of study treatment - Live vaccine within 4 weeks of study treatment - Active or unresolved adverse events - Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma - Female patients who are pregnant or breast-feeding at any time during the study - Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data